E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Severe COVID-19 Infection |
Infezione da COVID-19 grave |
|
E.1.1.1 | Medical condition in easily understood language |
Severe infection caused by a novel coronavirus COVID-19 |
Infezione grave causata dal nuovo coronavirus COVID-19 |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10051905 |
E.1.2 | Term | Coronavirus infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Day 14 Ordinal Time to Clinical Improvement (TTCI) |
Tempo fino al miglioramento clinico (TTCI) |
|
E.2.2 | Secondary objectives of the trial |
- Mortality - To determine the anti-inflammatory and immune effect of selinexor - To assess safety and tolerability of selinexor [time frame: up to 28 days] |
• Mortalità • Determinazone degli effetti antiinfiammatori e sul sitema immunitario di selinexor • Sicurezza e tollerabilità di Selinexor (fino a 28 giorni) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age =18 years 2. Clinically suspected and subsequently confirmed; or laboratory diagnosis confirming patient is positive for SARS-CoV2 nucleic acid by RT-PCR (by local labs) 3. Currently hospitalized and consented within the first 48 hours of hospitalization 4. Informed consent provided as above 5. Has symptoms of severe COVID-19 as demonstrated by: a. Respiratory rate =24 breaths/minute OR b. Pulse Oxygen Saturation (SpO2) =94% without oxygen inhalation, OR c. PaO2/FiO2 (fraction of inspired oxygen) =300 mm Hg 6. Concurrent anti-virals and/or anti-inflammatory agents are permitted at baseline for patients entering the study 7. Female patients of childbearing potential must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 1 week following the last dose of study treatment. Highly effective methods of contraception are listed in Protocol Section 8.3.1. |
1. Età = 18 anni 2. Sospetto clinico confermato successivamente oppure diagnosi di laboratorio che conferma che il paziente è positivo al virus SARS-CoV2 mediante rilevamento negli acidi nucleici della reazione a catena della polimerasi (PCR) con trascrittasi inversa (RT) (eseguito da laboratori a livello locale) 3. Soggetto ospedalizzato che presti il suo consenso entro 48 ore dall’ospedalizzazione 4. Consenso informato fornito secondo quanto riportato sopra 5. Sintomi severi da Covid-19 ovvero: a. frequenza respiratoria = 24 respiri/minuto OPPURE b. saturazione (SpO2) = 94% senza uso di ossigeno supplementare OPPURE c. PaO2/FiO2 (frazione inspiratoria di ossigeno) =300 mm Hg 6. La somministrazione concomitante di farmaci antivirali e/o antinfiammatori (ad es., biofarmaci, idrossiclorochina) è permessa al basale per i pazienti che vengono inseriti nello studio 7. Le pazienti in età fertile devono avere un test di gravidanza in siero negativo al momento dello screening. Le pazienti in età fertile e i pazienti fertili attivi sessualmente con donne in età fertile dovranno utilizzare metodi contraccettivi altamente efficaci durante tutta la durata dello studio e per una settimana dopo l’ultima dose del trattamento dello studio. I metodi contraccettivi altamente efficaci vengono riportati al punto 8.3.1 del protocollo. |
|
E.4 | Principal exclusion criteria |
1. Evidence of critical COVID-19 based on: a. Mechanical ventilation (invasive or non-invasive) or ECMO or hemofiltration required b. Shock 2. In the opinion of the investigator, unlikely to survive for at least 48 hours from screening or anticipate mechanical ventilation within 48 hours 3. Inadequate renal and liver function as indicated by the following labs: a. Creatinine clearance (CCL) <20 mL/min b. Aspartate transaminase (AST) or alanine transaminase (ALT) >5 x upper limit of normal (ULN) 4. Unable to take oral medication |
1. Evidenza di COVID-19 critica sulla base di: a. Necessità di ventilazione meccanica (invasiva o non invasiva), ossigenazione extracorporea a membrana (ECMO) o emofiltrazione b. Shock 2. Paziente che, secondo il parere dell’investigatore, abbia poche probabilità di sopravvivere per almeno 48 ore dopo lo screening o possa avere necessità di ventilazione meccanica entro 48 ore 3. Funzionalità renale ed epatica inadeguata secondo quanto indicato dai seguenti esami di laboratorio: a. Clearance della creatinina <20 ml/min. b. Valore di aspartato transaminasi (AST) o di alanina transaminasi (ALT) superiore a 5 volte il limite superiore di normalità (LSN) 4. Non in grado di assumere farmaci per via orale |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Absence of fever, oral temperature <38°C x 24 hours without antipyretics (acetaminophen) AND one of the following: - Respiratory rate =24/minute OR - Oxygen saturation >94% on room air OR - Hospital discharge |
Assenza di febbre: temperatura orale <38°C per 24 ore senza antipiretico (paracetamolo) NONCHÉ uno dei criteri indicati di seguito: - Frequenza respiratoria =24/minuto OPPURE - Saturazione di ossigeno =94% in aria ambiente OPPURE - Dimissione dall’ospedale |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Throughout the study |
Durante il corso dello studio |
|
E.5.2 | Secondary end point(s) |
• All-cause mortality by D 28 after randomization • Rate of mechanical ventilation • Length of hospitalization • Length of ICU stay • Duration of oxygen supplementation • Duration of mechanical ventilation • Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission • Vivi Disease Score • TTCI in patients =70 years old • TTCI in patients >70 years old • TTCI in patients that are immune compromised, have hypertension, or have pulmonary disease (smoking history or moderate to severe COPD) • Reduction of C-reactive protein (CRP) • Reduction in ferritin levels • LDH • Listing and documentation of frequency and severity of adverse effects |
• Mortalità per tutte le cause entro il 28º giorno dalla randomizzazione • Velocità e durata della ventilazione meccanica • Durata dell’utilizzo di ossigeno supplementare • Durata del ricovero ospedaliero • Durata della permanenza in terapia intensiva • Tempo fino al fallimento clinico, definito come il tempo fino al decesso, all’inizio della ventilazione meccanica o al trasferimento in terapia intensiva • Punteggio “Vienna Vaccine Safety Initiative (ViVI)” di gravità della malattia • TTCI in pazienti di età =70 anni • TTCI in pazienti di età >70 anni • TTCI in pazienti immunodepressi, ipertesi o affetti da malattia polmonare (fumatori o con broncopneumopatia cronica ostruttiva [BPCO] da moderata a grave) • Effetti sul livello di proteina C reattiva (PCR) • Effetti sul livello di ferritina • Effetti sulla lattato deidrogenasi (LDH) • Elencazione e documentazione della frequenza e gravità degli effetti avversi |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Mortality at day 28 Rest of endpoints during the course of the study |
Mortalità = al giorno 28 Gli altri endpoints = durante il corso dello studio |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Arruolamento stratificato per: area geografica e uso di terapie concomitanti |
enrollment stratified by: Use of concomitant therapies and High Risk Comorbidities |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Austria |
Belgium |
Canada |
France |
Germany |
India |
Israel |
Italy |
Malaysia |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
A patient will be considered having completed the study if he/she has completed up to 14 days of therapy (or 28 days per treating physician's discretion) or died. |
Completamento del trattamento fino a 14 giorni di terapia (o 28 giorni a discrezione dell’Investigatore) o morte |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |